Robert Talac: Is PRP Truly Autologous?
Robert Talac, Medical Director at Renaxis Regenerative Orthopedic Center, shared a post on LinkedIn:
“PRP Is Not Fully Autologous.
We should probably talk about that.
I’ve been in regenerative medicine for over 30 years.
For most of that time, PRP was widely accepted as the gold standard of autologous biologics.
I want to challenge that.
Here’s what’s actually in a standard PRP preparation:
- Citrate or EDTA anticoagulants (not from the patient)
- Bovine thrombin as an activator (not from thepatient)
- Calcium chloride to trigger clotting (not from the patient)
None of these are autologous. And it’s not a minor footnote.
EDTA and citrate disturb natural ionic homeostasis and alter cytokine profiles.
Bovine thrombin carries a documented immunogenicity risk, potentially triggering antibody responses against the patient’s own clotting factors.
This is not a fringe concern. It’s in the published data.
Platelet-Rich Fibrin (PRF), by contrast, uses no anticoagulant.
- Blood is drawn and immediately centrifuged.
- Clotting occurs through physiologic thrombin alone.
- No external activator, no foreign additive, no biochemical modification.
One caveat worth naming: many commercial PRF kits use silica or silicone-coated tubes as clot activators.
Those are foreign materials, too.
Which is why I use plain glass tubes (Bio-PRF) – the only truly additive-free option.
The result?
A dense autologous platelet-rich fibrin matrix. Nothing added. Nothing altered.
We’ve spent decades debating PRP activation protocols, platelet concentrations, and leucocyte ratios. Maybe the more important question is simpler:
If autologous therapy is the goal – is PRP actually”

Stay updated with Hemostasis Today.
-
Nov 8, 2026, 12:22Marc Carrier: Advancing Catheter-Related Thrombosis Prevention Through Factor XI Inhibition
-
Nov 8, 2026, 11:56Why Genetic Predisposition Does Not Always Lead to Thrombosis – Stork Genetics
-
Nov 8, 2026, 11:45Sher-Lu Pai: Investigating Intracardiac Thrombosis and Its Management in Liver Transplantation
-
Nov 8, 2026, 11:25Mehmet Cilingiroglu: Navigating Anticoagulation Choices in Acute Coronary Syndrome PCI
-
Nov 8, 2026, 07:16Gilberto de lima Lopes Junior: The Cardiovascular Consequences of Cancer in Younger Patients
-
Nov 8, 2026, 06:51Haney Mallemat: Key Principles and Pitfalls of LVAD Emergencies
-
Nov 8, 2026, 06:31Maria Omer: Clinical Recognition and Management of Cavernous Sinus Thrombosis
-
Nov 8, 2026, 06:16Natasha Jolakoski: University of New Mexico Hospital Promotes PGY-2 Thrombosis and Hemostasis Management Pharmacy Residency
-
Nov 8, 2026, 05:47Safaa Hilal: POCUS in the Evaluation of Perioperative Troponin Elevation